Oncoscience | Association between tumor mutations and meningioma recurrence in Grade I/II disease | 腫瘤科學 | I/II 級疾病中腫瘤突變與腦膜瘤復發的關聯

中文版谷歌中文翻譯(90% 準確率) | English translation
Buy/Sell Your Domains Here。在這裡購買/出售您的域名
Contact Dr. Lu for information about cancer treatments。聯繫盧博士,獲取有關癌症治療資訊。
NEWS RELEASE 

So what causes the tumor mutations?  Treatments! The majority of treatments including chemo and radiation therapy are cancer causing agents. The more you get treated, the more likely you will get cancer.

那麼是什麼導致了腫瘤突變呢? 治療! 包括化學療法和放射療法在內的大多數治療都是致癌劑。 您接受的治療越多,您患癌症的可能性就越大。

Peer-Reviewed Publication

IMPACT JOURNALS LLC

Figure 2
IMAGE: FIGURE 2: ADJUSTED PROGRESSION-FREE SURVIVAL HAZARD RATIOS FOR GENES EXAMINED. view more 

CREDIT: 2022 DULLEA ET AL.

“Though meningioma patients often see favorable oncological outcomes, many tumors still recur post-surgically.”

BUFFALO, NY- January 17, 2023 – A new research paper was published in Oncoscience (Volume 9) on December 9, 2022, entitled, “Association between tumor mutations and meningioma recurrence in Grade I/II disease.”

Meningiomas are common intracranial tumors with variable prognoses not entirely captured by commonly used classification schemes. In this new study, researchers Jonathan T. Dullea, Vikram Vasan, John W. Rutland, Corey M. Gill, Danielle Chaluts, Daniel Ranti, Ethan Ellis, Varun Subramanium, Annie Arrighi-Allisan, Yayoi Kinoshita, Russell B. McBride, Joshua Bederson, Michael Donovan, Robert Sebra, Melissa Umphlett, and Raj K. Shrivastava from Icahn School of Medicine at Mount Sinai and Sema4 (A Mount Sinai Venture) sought to determine the relationship between meningioma mutations and oncologic outcomes using a targeted next-generation sequencing panel.

“As such, there is a need to further characterize meningioma disease mechanisms in pursuit of better diagnostics and novel targets to improve treatment paradigms.”

The team identified 184 grade I and II meningiomas with both >90 days of post-surgical follow-up and linked targeted next-generation sequencing. For mutated genes in greater than 5% of the sample, progression-free survival Cox-regression models stratified by gene were computed. They then built a multi-gene model by including all gene predictors with a p-value of less than 0.20. Starting with that model, the researchers performed backward selection to identify the most predictive factors.

ATM (HR = 4.448; 95% CI: 1.517–13.046), CREBBP (HR = 2.727; 95% CI = 1.163–6.396), and POLE (HR = 0.544; HR = 0.311–0.952) were significantly associated with alterations in disease progression after adjusting for clinical and pathologic factors. In the multi-gene model, only POLE remained a significant predictor of recurrence after adjusting for the same clinical covariates. Backwards selection identified recurrence status, resection extent, and mutations in ATM (HR = 7.333; 95% CI = 2.318–23.195) and POLE (HR = 0.413; 95% CI = 0.229–0.743) as predictive of recurrence.

“Mutations in ATM and CREBBP were associated with accelerated meningioma recurrence, and mutations in POLE were protective of recurrence. Each mutation has potential implications for treatment. The effect of these mutations on oncologic outcomes and as potential targets for intervention warrants future study.”

 

DOI: https://doi.org/10.18632/oncoscience.570

Correspondence to: Jonathan T. Dullea – Email: [email protected]

Keywords: meningioma, molecular genomics, POLE, ATM, CREBBP
About Oncoscience:

Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: Freeing oncology from publication cost. It is free for the readers and the authors.

To learn more about Oncoscience, visit Oncoscience.us and connect with us on social media:

 

For media inquiries, please contact [email protected].

 

Oncoscience Journal Office

6666 East Quaker Str., Suite 1D

Orchard Park, NY 14127

Phone: 1-800-922-0957, option 4

###


$$$ If you are interested in a writer or editor position, check out here.We are hiring. $$$

1

No Responses

Write a response

16 − six =